Robert Weisman
Robert Weisman
Boston Globe Staff
Weisman covers the healthcare and life sciences industries for the Globe's Business section. He was a business reporter and editor for the Hartford Courant and the Seattle Times before joining the Globe in 2000.

Stories by Robert Weisman

Biogen Idec chief warns drug development could be hurt by cuts in funding and reimbursments
Biogen chief executive George Scangos (company photo)
CAMBRIDGE -- The top executive of Biogen Idec Inc. said Thursday that the state’s drug makers are producing breakthrough treatments for conditions ranging from multiple sclerosis to hepatitis C to hemophilia. But he warned future innovation is threatened by federal funding cuts for basic research and payments that don’t allow companies to recover their investments. Read More
New collaboration deal gives Celgene option to acquire Forma Therapeutics of Watertown
One year after it struck an agreement to collaborate with New Jersey-based Celgene Corp. to make drugs that regulate the level of proteins in cells, Forma Therapeutics of Watertown said it has reached a second deal to work with Celgene across a range of therapeutic areas. The new deal gives Celgene an exclusive option to acquire Forma at some time in the future. Read More